knowledge -WSS

knowledge

author：focus 2025-09-02 08:24:46 - browse：1116

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Readout LOUD: Venture capital, Gilead, and more M&A

hotspot

WSS

AstraZeneca stays mum on Medicare drug pricing negotiations

The Biogen Aduhelm mess could happen again

The CDC's new social media misinformation war

Mass General totes up its waste in a move to tackle climate change

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

A single Democrat is willing to weaken Medicare negotiation power

knowledge

knowledge

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

AstraZeneca stays mum on Medicare drug pricing negotiations

Hepatitis C has a cure — but many Americans still lack access to it

Top private equity targets in 2023: cardiology, clinical trials, lasers

DIEP, the 'gold standard' of breast reconstruction, is under threat

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Bright Health sells Medicare Advantage business to Molina

Driven by the pandemic, applicants flood public health schools

ChatGPT in medicine: STAT answers readers' burning questions

Top private equity targets in 2023: cardiology, clinical trials, lasers

focus

Texas Department of Public Safety speaks out on migrant abuse allegations

7 more heat

Tocagen's brain cancer gene therapy trial continues. Investors worry

AstraZeneca stays mum on Medicare drug pricing negotiations

AI gets buy

7 more heat

explore

Wikipedia

hotspot

hotspot